• Gianluca Lazzaro, Roberta Lazzari, Giuseppe Pelosi, Tommaso De Pas, Luigi Mariani, Giovanni Mazzarol, Daniele Sances, Giulio Tosti, Federica Baldini, Massimo Mosconi, Ines Tedeschi, Giuseppe Viale, Hugo Marsiglia, Antonio Chiappa, Andrea Vavassori, Roberto Orecchia, and Alessandro Testori.
• Melonoma Unit, European Institute of Oncology, University of Milan, Via Ripamonti 435, 20141 Milan, Italy,
• Ann. Surg. Oncol. 2005 Nov 1; 12 (11): 935-42.

BackgroundThis study evaluated the role of pulsed dose-rate (PDR) brachytherapy (BRT), delivered alone or as a boost to external beam radiotherapy, as adjuvant therapy for the local control of soft tissue sarcomas of the extremities and skeletal muscles of the trunk that have undergone surgical treatment.MethodsBetween July 1998 and January 2002, 42 patients were treated with a combination of surgery and BRT alone (18 patients) or BRT/external beam radiotherapy (24 patients) for the treatment of primary (n = 32) and recurrent (n = 10) soft tissue sarcomas located in the proximal extremity (n = 17), distal extremity (n = 17), and trunk (n = 8). Tumor size was <5 cm in 20 cases and >5 cm in 22 cases, with histological grading of 1 (n = 7), 2 (n = 18), or 3 (n = 17). The median BRT dose delivered was 15 Gy, and the median external beam irradiation dose was 50 Gy.ResultsWith a median follow-up of 34 months, the 36-month survival was 83.9% (SE, 6.1%), and the local control was 89%.ConclusionsPDR interstitial BRT for soft tissue sarcoma is an effective, well-tolerated adjuvant radiation treatment that offers several practical advantages, among which are low acute and late toxicity with maximum normal tissue and critical structure sparing and overall shorter radiotherapy and hospital stay.

26 keywords...

hide…